Ranolazine for elevated brain-type natriuretic peptide

Details for Australian Patent Application No. 2008260480 (hide)

Owner CV Therapeutics, Inc.

Inventors Blackburn, Brent; Jerling, Marcus; Wolff, Andrew

Agent Freehills

Pub. Number AU-A-2008260480

PCT Pub. Number WO2008/150565

Priority 60/941,210 31.05.07 US

Filing date 24 March 2008

Wipo publication date 11 December 2008

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

7 January 2010 PCT application entered the National Phase

  PCT publication WO2008/150565 Priority application(s): WO2008/150565

2 February 2012 Assignment before Grant

  CV Therapeutics, Inc. The application has been assigned to Gilead Sciences Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008260481-Cold row encapsulation for server farm cooling system

2008260467-Apparatus and method for top removal of granular and fine material from a fluidized bed deposition reactor